Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its proprietary cell penetrating peptide (CPP) technology platform. The company's lead product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin to the mitochondria of patients with Friedreich's ataxia. The CPP platform enables therapeutic molecules to cross cell membranes to reach intracellular targets, with plans to apply this technology to other orphan indications characterized by intracellular protein deficiencies. The company has received Orphan Drug Designation, Fast Track Designation, and Breakthrough Therapy Designation from the FDA, as well as access to the EMA's PRIME scheme and the UK's ILAP pathway. Nomlabofusp is currently being evaluated in a Phase 2 clinical program, with ongoing studies in adults and adolescents. The company has also engaged in discussions with the FDA regarding the use of frataxin concentration as a surrogate endpoint for accelerated approval.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage larimartx.com
Sector Healthcare IR page investors.larimartx.com
Tags
rare diseases, friedreich's ataxia, protein replacement therapy, cell penetrating peptides, intracellular delivery, clinical-stage, orphan drugs, genetic disorders, nomlabofusp, CTI-1601, frataxin, CPP technology platform
Press page larimartx.com/news

Metrics

Valuation  
Market cap $ 317.441M
Market cap (USD) $ 317.441M
P/E -2.03
PEG —
P/BV 3.13
P/S —
P/OCF -2.80
P/FCF -2.80
Dividend yield —
Turnover / mcap —
Returns  
ROE -132.6%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 28
Quality score -70.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Assets 145.842M 200.225M 95.935M 126.405M 78.667M 104.686M 80.734M 121.762M 105.51M 131.621M 189.106M 117.519M 38.138M
Net profit -165.673M -80.604M -36.949M -35.355M -50.636M -42.482M -45.406M -61.368M -52.028M -57.878M -74.286M -36.478M -14.027M
Free cash flow -113.292M -71.275M -33.623M -27.669M -42.438M -42.261M -41.547M -51.595M -43.839M -52.635M -60.149M -28.299M -15.021M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 3.81 3.87 4.55 4.13 10.79 21.41 1.11 4.95 4.62 3.18 6.29 30.84 —
Price performance 12m -0.02 -0.15 0.1 -0.62 -0.5 18.29 -0.78 0.07 0.45 -0.49 -0.8 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 6.84M 6.52M 6M 5.41M 5.55M 5.12M 4.07M
Cash and deposits (USD) 32.4M 40.8M 49.3M 27.2M 68.1M 70.1M 26.8M 26.7M 33.2M 85.4M
Right-of-use assets (USD) — — — 7.05M 3.94M 3.41M 2.86M 3.08M 2.84M 2.07M
Cash flow detail
Operating cash flow (USD) -52M -43.8M -51.5M -40.8M -42.2M -42.1M -27.6M -33.5M -70.8M -113M
Purchases of property, plant and equipment (USD) -660,000 -55,000 -108,000 -764,000 -62,000 -333,000 -100,000 -164,000 -515,000 -91,000
Change in payables (cash effect) (USD) -4.63M 448,000 432,000 -2.96M -3.29M -974,000 26,000 -403,000 1.14M 2.79M
Interest paid (cash effect) (USD) -388,000 -141,000 -1.14M -1.22M — — — — — —
Share-based compensation (USD) 10.1M 8.3M 9.63M 5.5M 2.16M 5.47M 6.62M 7.62M 8.8M 7M
Free cash flow (OCF - PPE - intangibles) (USD) -52.6M -43.8M -51.6M -41.5M -42.3M -42.4M -27.7M -33.6M -71.3M -113M
Income detail
Research and development expense (USD) 39.9M 40.8M 47.9M 23.9M 31.4M 38.4M 24.3M 27.7M 73.3M 154M
↳ 5y CAGR +28.7% +38.0% -2.7% -10.5% -0.8% -9.9% -10.4% +25.1% +37.5%
Total comprehensive income (USD) -57.8M -52M -61.3M -45.3M -42.5M -50.6M -35.4M -36.8M -80.5M -166M
Comprehensive income to owners (USD) -57.8M -52M -61.3M -45.3M -42.5M -50.6M -35.4M -36.8M -80.5M -166M
Reported Mar 10, 2017 Mar 9, 2018 Mar 14, 2019 Mar 5, 2020 Mar 4, 2021 Mar 25, 2022 Mar 14, 2023 Mar 14, 2024 Mar 24, 2025 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause of disease

•Previously disclosed FDA alignment on key BLA elements, including willingness to consider skin frataxin as a potential novel surrogate endpoint

•Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp

•$128.7 million in cash, cash equivalents and marketable securities as of September 30, 2026, with projected cash runway into late Q2 2027

Bala Cynwyd, PA, November 16, 2026 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2026 operating and financial results.

“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community,” said Carole Ben-Maimon, M.D., Chief Executive Officer of Larimar.

•Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA

•Submission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpoint

•Previously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natural history reference population

•Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp

Bala Cynwyd, PA, November 9, 2026 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich’s ataxia (FA).

The Board of Directors (the “Board”) of Larimar Therapeutics, Inc. (the “Company”) appointed John B. Harlow, Jr. as the Company’s President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow (the “Employment Agreement”), effective as of September 29, 2026 (the “Effective Date”).

Prior to joining the Company, Mr. Harlow, age 51, served as the Chief Commercial Officer at Esperion Therapeutics, Inc. (formerly Nasdaq: ESPR), a commercial stage biopharmaceutical company focused on developing medicines for patients who are at risk for cardiovascular disease, from November 2025 to September 2026, where he led commercial operations, business development and global alliance management. From March 2021 to November 2025, Mr. Harlow served as the Chief Commercial Officer of Melinta Therapeutics, LLC, a commercial stage company focused on innovative therapies for acute and life-threatening illnesses, where he built a robust commercial infrastructure with a high-performing team while achieving significant revenue growth and sustained profitability ahead of its 2025 acquisition by CorMedix. From November 2019 to March 2021, Mr.

Prompts

Larimar Therapeutics, Inc. (ticker LRMR), listed in United States.

Company History

Date Change Detail
Apr 6, 2020 Renamed ZAFGEN, INC. → LARIMAR THERAPEUTICS, INC.

ETFs Holding Larimar Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
FSCC 0.11% 103,261 $ 394.457K Aug 31, 2026
FSEV 0.05% 1,097 $ 3,345.85 Jun 30, 2026
FESM 0.04% 814,618 $ 2.485M Jun 30, 2026
FSEG 0.04% 800 $ 2,440.00 Jun 30, 2026
FEAC 0.04% 3,467 $ 10.574K Jun 30, 2026
RESM 0.00% 59 $ 179.95 Jun 30, 2026
DFAS 0.00% 508,215 $ 1.372M Nov 12, 2026
DXUV 0.00% 37,798 $ 102.055K Nov 12, 2026
DFAC 0.00% 120,879 $ 326.373K Nov 12, 2026
DCOR 0.00% 16,124 $ 43.535K Nov 12, 2026
AVSC 0.00% 17,983 $ 53.949K Nov 16, 2026